Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1 -high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder value CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and... Read More

CAMBRIDGE, Mass. , May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter of 2025. Leap Highlights: Reported positive data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line... Read More

FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical models Findings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinic CAMBRIDGE, Mass. , April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. ( Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501... Read More

Virtual KOL Event on Wednesday, April 23, 2025 , at 2:30 p.m. ET CAMBRIDGE, Mass. , April 15, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will host a virtual key opinion leader (KOL) event featuring Zev A. Wainberg , MD, Professor of Medicine at University of California, Los Angeles ( UCLA ) and... Read More

Leap to host a conference call to present updated CRC clinical data today, March 26, 2025 , at 8:00 a.m. ET CAMBRIDGE, Mass. , March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024 . Leap Highlights: Reported positive updated data... Read More

Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy Statistically significant 22% higher ORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy Leap to host a conference call to present clinical data today, March 26, 2025 , at 8:00 a.m. ET CAMBRIDGE, Mass.... Read More

35% objective response rate ( ORR ) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC... Read More

CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will present a corporate overview at the 43 rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Leap Presentation Details: 43 rd Annual J.P. Morgan Healthcare... Read More

CAMBRIDGE, Mass. , Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36 th Annual Healthcare Conference in New York, NY . Leap Presentation Details: Piper Sandler 36 th Annual... Read More

CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024 . Leap Highlights: Completed enrollment in the expanded randomized controlled Part B of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti- DKK1 monoclonal... Read More

CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy... Read More

CAMBRIDGE, Mass. , Aug. 12 , 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024 . Leap Highlights: Overall response rate (ORR) increases to 33% across all evaluable patients and 38% across evaluable patients with left-sided CRC in updated data from Part... Read More

CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024 . Leap Highlights: Completed $40 million private placement financing with participation from Gilead Sciences, Inc., a life sciences-focused investor, Samsara BioCapital, 683... Read More

Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program CAMBRIDGE, Mass. , April 11, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a... Read More

CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023 . Leap Highlights: Presented new clinical data from Part A of the Phase 2 DeFianCe study evaluating DKN-01 in combination with standard of care bevacizumab and... Read More

30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR , 100% DCR, and preliminary median PFS of 9.4 months. Leap to host conference call to report additional clinical data including further subgroup analyses on Tuesday, January 23, 2024 at... Read More

CAMBRIDGE, Mass. , Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will present a corporate overview at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Leap Presentation Details: 42 nd Annual J.P. Morgan Healthcare... Read More

CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy... Read More

CAMBRIDGE, Mass. , Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of... Read More

CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference in New York, NY . Leap Presentation Details: Piper Sandler 35 th Annual... Read More

CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023 . "Leap continued to make great strides this quarter including advancing into the 130 patient, randomized controlled Part B of the DeFianCe study evaluating DKN-01 plus... Read More

CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, will participate in two upcoming investor conferences: Leap Presentation Details: H.C. Wainwright 25 th Annual Global Investment Conference Date: Monday, September 11 th ,... Read More

CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second quarter ended June 30, 2023 . Leap Highlights: Announced that initial data from Part A of the Phase 2 DeFianCe study of DKN-01 in combination with standard of care bevacizumab and chemotherapy as a... Read More

CAMBRIDGE, Mass. , July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (CRC) in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study. The study... Read More

CAMBRIDGE, Mass. , June 20, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will effect a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023 . Leap expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market... Read More

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass. , May 25, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology... Read More

CAMBRIDGE, Mass. , May 15, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for first quarter ended March 31, 2023 . Leap Highlights: Presenting new long-term follow-up data from Part A of the Phase 2 DisTinGuish study of DKN-01 plus tislelizumab and chemotherapy in first-line patients with... Read More

CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new long-term follow-up data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from Part A of the DisTinGuish study, a Phase 2 clinical trial evaluating Leap's... Read More

CAMBRIDGE, Mass. , April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in Part A of the Phase 2 DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for... Read More

CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2022 . Leap Highlights: Acquired Flame Biosciences, adding FL-301, a clinical stage anti-Claudin18.2 antibody, and preclinical antibody programs targeting... Read More

DisTinGuish Trial of DKN-01 plus tislelizumab and chemotherapy to continue as a clinical collaboration CAMBRIDGE, Mass. , March 16, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that BeiGene's option under the Exclusive Option and License Agreement between Leap and BeiGene granting rights in certain Asian... Read More

Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m. ET today CAMBRIDGE, Mass. , Jan. 17, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing... Read More

CAMBRIDGE, Mass. , Jan. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi , President and Chief Executive Officer, Cynthia Sirard , MD, Chief Medical Officer, and Jason Baum , PhD., Vice President and Head of Translational Medicine will present a corporate overview at B. Riley... Read More